The problem
Environmental and metabolic exposure history is invisible to standard diagnostics, and pediatric neurological workups in the Kingdom rely on panels calibrated to other populations.
Our approach
Localization of an existing platform through a Kingdom entity, with the assay validated against Saudi pediatric and neurological cohorts rather than adapted after launch.
Where it stands
Entity live. Cohort validation underway ahead of an SFDA submission.
Stage descriptions reflect the studio's internal classification and are updated quarterly. Regulatory status is determined solely by the Saudi Food and Drug Authority.
More in Biotech
KaRama Bio
Bio platform · built in houseOur own bio platform, built in house on Saudi clinical data.
Bio Aro
Precision medicine · microbiomePrecision medicine and microbiome diagnostics, brought into the Kingdom through a joint venture.
Allergenix
Allergy diagnostics · immunotherapyAllergy diagnostics and immunotherapy built around the regional allergen profile.